Hemodynamics, fluids & transfusion
Erythropoietin to treat anaemia in critical care patients: a multicentre feasibility study
Authors' conclusion
A large, multicentre randomised controlled trial of erythropoietin to treat anaemia in ICU patients is feasible and necessary to determine effects of erythropoietin on mortality in ICU anaemic patients.
Study context
- Population
- ICU patients staying ≥ 72 h with haemoglobin ≤ 120 g.l-11 withdrew consent
- Participants
- 42 patients
- Comparison
- Weekly erythropoietin vs placebo
- Erythropoietinn = 20
- Placebon = 21reference
- Primary endpoint
- Feasibility (recruitment, randomisation and follow-up rates, and protocol compliance)
Methodological detailsfeasibility study, multicentre, placebo-controlled
- Feasibility study
- Multicentre
- Placebo-controlled
Primary result
As reported in the abstract
Feasibility
Overall recruitment rate
73.7%
Participants recruited on average per month
8.4
Secondary outcomes
Last Hb before hospital discharge (or death)
- Similar between the groups
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Erythropoietin to treat anaemia in critical care patients: a multicentre feasibility study. Anaesthesia. Published 15 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →